Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1.

Department of Obstetrics and Gynecology, University of Pennsylvania Medical Center, Philadelphia, PA 19104, USA.
New England Journal of Medicine (Impact Factor: 54.42). 12/1996; 335(19):1413-6. DOI: 10.1056/NEJM199611073351901
Source: PubMed

ABSTRACT We tested the hypothesis that ovarian cancers associated with germ-line mutations of BRCA1 have distinct clinical and pathological features as compared with sporadic ovarian cancers.
We reviewed clinical and pathological data on patients with primary epithelial ovarian cancer found to have germ-line mutations of BRCA1. Survival among patients with advanced-stage cancer and such mutations was compared with that in control patients matched stage, grade, and histologic subtype of the tumors. A combination of single-strand conformation and sequencing analyses was used to examine the 22 coding exons and intronic splice-donor and splice-acceptor regions of BRCA1 for mutations in pathological specimens. Alternatively, some patients were known to be obligate carriers of the mutant BRCA1 gene because of their parental relationships with documented mutant-gene carriers.
We identified 53 patients with germ-line mutations of BRCA1. The average age at diagnosis was 48 years (range, 28 to 78). Histologic examination in 43 of the 53 patients showed serous adenocarcinoma. Thirty-seven tumors were of grade 3, 11 were of grade 2, 2 were of grade 1, and 3 were of low malignant potential. In 38 patients, the tumors were of stage III; 9 patients (including those with tumors of low malignant potential) had stage I disease, 5 had stage IV, and 1 had stage II. As of June 1996, with a median follow-up among survivors of 71 months from diagnosis, 20 patients had died of ovarian cancer, 27 had no evidence of the disease, 4 were alive with the disease, and 2 had died of other diseases. Actuarial median survival for the 43 patients with and advanced-stage disease was 77 months, as compared with 29 months for the matched controls (P<0.001).
As compared with sporadic ovarian cancers, cancers associated with BRCA1 mutation appear to have a significantly more favorable clinical course.

  • Journal of Clinical Oncology 01/2002; 20(8):2092-2100. · 17.88 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Das Ovarialkarzinom wird zumeist in fortgeschrittenem Stadium mit entsprechend schlechter Prognose diagnostiziert. Prävention und Screening könnten diesen fatalen Verlauf beeinflussen. Charakterisierung und Identifikation der Risikogruppen, bereits verfügbare präventive Maßnahmen fördern und mögliche in Studien evaluieren, Verbesserung der Diagnostik und Evaluation möglicher Screeningmethoden – dies sind einige Aspekte des Problemfeldes. Betrachtet werden hormonelle Kontrazeption, weitere endokrine und chemopräventive Optionen sowie chirurgische Aspekte. Die Bedeutung von nichthereditären Risiken, welche die Inzidenz des Ovarialkarzinoms erhöhen, wird erörtert. Bereits heute bestehen Interventions- und Vermeidungsmöglichkeiten zur Prävention des Ovarialkarzinoms, die mit diagnostischen Maßnahmen verbunden werden können. Sekundär- und Tertiärprävention werden diskutiert.
    Der Gynäkologe 01/2008; 41(7).
  • [Show abstract] [Hide abstract]
    ABSTRACT: Cette mise au point des connaissances actuelles permet d’individualiser certaines tumeurs malignes rares de l’ovaire (TMRO) et de préciser les indications de consultation d’oncogénétique pour les cliniciens. Contrairement aux cancers de l’ovaire classiques survenant à un âge jeune évoquant une mutation des gènes BRCA ou un syndrome de Lynch, la découverte d’une tumeur rare de l’ovaire même à un âge jeune n’évoque pas forcément une origine génétique et est le plus souvent sans rapport avec ces maladies génétiques. Abstract This development of the current knowledge allows individualizing some rare malignant ovarian tumors and specifying the indications of oncogenetics consultation for the clinicians. Contrary to the classic ovarian cancers arising at a young age evoking a BRCA mutation, the discovery of a rare ovarian tumor at a young age does not evoke necessarily a genetic origin and mostly without relationship with the BRCA genes.
    Oncologie 06/2014; 16(6):330-334. · 0.08 Impact Factor